MarketMoodz
Aardvark Therapeutics Stock Sinks on HERO Trial Pause and Safety Review
Aardvark Therapeutics paused its Phase 3 HERO trial for Prader-Willi Syndrome to undergo a comprehensive safety data review after reversible cardiac observations at higher-than-target doses in a healthy-volunteer study. Premarket trading shows the stock around $5.41-$5.51, down roughly 55-57% and near the year’s 52-week low as timelines for topline HERO data are being reassessed.
Key Takeaways
- Aardvark paused the HERO Phase 3 program to review safety data after reversible cardiac signals at elevated doses.
- Premarket action put the stock around $5.41-$5.51, down ~55-57% and near a $4.88 52-week low.
- Topline HERO data originally expected in Q3 2026 has been delayed and the timeline is under reassessment.
- CEO Tien Lee emphasizes patient safety and FDA collaboration while determining next steps.
- Downgrades from RBC Capital, Stifel, Morgan Stanley and HC Wainwright on Mar 2 place downside targets near $6-$7 while consensus still pointed to a higher price prior to the pause.
People Involved
- Tien Lee CEO, Aardvark Therapeutics
Entities Involved
- Aardvark Therapeutics Inc. (AARD) Biotech company developing ARD-101 for Prader-Willi syndrome
- FDA Regulatory agency overseeing drug approvals
- RBC Capital Investment bank that downgraded AARD (target $6)
- Stifel Investment bank that downgraded AARD (target $6)
- Morgan Stanley Investment bank that downgraded AARD (target $7)
- HC Wainwright Investment bank that downgraded AARD (Neutral)
MarketMoodz Analysis
The pause creates near-term sell-side pressure on AARD, as investors digest the safety signal and whether the risk/benefit profile of ARD-101 can be reframed. With more than half of the 90-patient HERO trial enrolled by mid-January, there is potential for early unblinding if safety concerns are resolved, which could unlock accelerated development options. But until safety data are clearly favorable, the stock remains highly sensitive to regulatory guidance and FDA interactions.
Historically, biotechnology Phase 3 pauses around safety events have produced sharp reversals in stock prices, followed by data-driven pivots if regulators clear the way for continued development. A return to momentum would depend on a clean safety readout and credible plans for a second pivotal trial if the current program falters. The next few weeks will hinge on safety resolution, communication with the FDA, and any strategic decisions on trial design or pivots.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial